Early treatment targeting left ventricular hypertrophy regression in chronic renal failure patients may reduce future cardiovascular events.
SUMMARY: Left ventricular hypertrophy is an important risk factor for cardiovascular disease, which is a major component of premature death among renal failure patients. Early treatment of progressive renal insufficiency has the opportunity to attempt prevention of, or reduction in, the development of LVH. Therapies specifically targeted at regression of LVH (e.g. antihypertensive regimens and epoetin‐α) may, therefore, impact favourably on future cardiovascular events. Importantly, these approaches appear complementary and should be used in unison to maximize cardiovascular risk reduction in renal failure patients.
No takes yet. Share an insight, caveat, or question.
Krum et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: